trending Market Intelligence /marketintelligence/en/news-insights/trending/5DdQy28R3AJ7K7wVWzPASw2 content esgSubNav
In This List

Parnell Pharmaceuticals delisting from Nasdaq

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Parnell Pharmaceuticals delisting from Nasdaq

Australia-based Parnell Pharmaceuticals Holdings Ltd. will delist from the Nasdaq, effective Dec. 31.

The company said it believes that there has been an incongruence between the potential realizable value of Parnell's underlying assets and its share price as a Nasdaq-listed company, according to a news release.

The veterinarian pharmaceutical company anticipates its shares to be quoted on the OTC Pink open market following the delisting.